Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

187

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
A08AB01	ONLEFIT	G	Orlistat - 120mg	120mg	Capsule	1,537,356 L.L
A08AB01	ORLISTAT	G	Orlistat - 120mg	120mg	Capsule, hard	847,965 L.L
A08AB01	ORLISTAT-SIGMA	G	Orlistat - 120mg	120mg	Capsule	847,965 L.L
A08AB01	ORLY SLIM	G	Orlistat - 120mg	120mg	Capsule	1,174,518 L.L
A08AB01	UNI-CAL	G	Orlistat - 120mg	120mg	Capsule	1,174,518 L.L
A08AB01	LESSFAT	G	Orlistat - 60mg	60mg	Capsule	1,039,238 L.L
A09AA02	CREON 10,000	B	Pancreatin protease - 600FIP-U, Pancreatin amylase - 8,000FIP-U, Pancreatin lipase - 10,000FIP-U		Capsule	1,835,689 L.L
A09AA02	CREON 25,000	B	Pancreatin protease - 1000FIP-U, Pancreatin amylase - 18000FIP-U, Pancreatin lipase - 25000FIP-U		Capsule	4,598,629 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
A10AB01	HUMULIN R U-100	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	701,486 L.L
A10AB01	JUSLINE R	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	401,809 L.L
A10AB04	HUMALOG KWIKPEN	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable solution	3,950,897 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable solution	637,365 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable solution	2,126,343 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable solution	883,480 L.L
A10AB04	HUMALOG	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable suspension	1,988,887 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable suspension	1,503,312 L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
A10AB06	APIDRA SOLOSTAR	BioTech	Insulin glulisine - 100IU/ml	100IU/ml	Injectable solution	3,942,834 L.L
A10AB06	APIDRA	BioTech	Insulin glulisine - 100IU/ml	100IU/ml	Injectable solution	2,221,372 L.L
A10AD01	HUMULIN 70/30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	701,486 L.L
A10AD01	JUSLINE	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	401,809 L.L
A10AD01	MIXTARD 30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
A10AD01	MIXTARD 30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
A10AD04	HUMALOG MIX 50 KWIKPEN	BioTech	Insulin lispro solution - 50%, Insulin lispro protamine suspension - 50%	100IU/ml	Injectable suspension	3,950,897 L.L
A10AD04	HUMALOG MIX 25 KWIKPEN	BioTech	Insulin lispro solution - 25%, Insulin lispro protamine suspension - 75%	100IU/ml	Injectable suspension	3,950,897 L.L
A10AD05	NOVOMIX 30	BioTech	Insulin aspart - 30%, Insulin aspart protamine - 70%	100IU/ml	Injectable suspension	4,264,012 L.L

...

187